查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1631384

子宫癌症诊断检验的全球市场:产业分析，规模，占有率，成长，趋势，预测(2025年～2032年)

Uterine Cancer Diagnostic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 241 Pages | 商品交期: 2-5个工作天内

价格
简介目录

2025年，全球子宫癌诊断检测市场规模预计为35.471亿美元，2025-2032年预测期间复合年增长率为9.60%，到2032年将达到67亿美元。万。

全球子宫癌诊断测试市场包括旨在检测子宫内膜癌和子宫内膜癌（包括子宫肉瘤）的超音波检查、活检方法和血液检查等诊断解决方案。子宫内膜癌盛行率的增加、诊断技术的进步以及老年人口的增加推动了市场的成长。医疗保健基础设施、意识计划和政府措施的改善也支持市场扩张。

有几个因素正在推动全球子宫癌诊断测试市场的成长。子宫内膜癌的盛行率不断上升，特别是在停经后和肥胖女性中，强调了早期检测方法的必要性。经阴道超音波扫描和 CA125 肿瘤标记血液检测等诊断技术的进步提高了准确性和可靠性，刺激了市场推广。增加医疗保健支出，尤其是在新兴经济体，支持诊断解决方案的开发和可近性。此外，政府促进妇女健康和癌症筛检以及提高早期诊断意识的措施也对市场成长做出了重大贡献。

由于技术进步和医疗保健服务范围的扩大，子宫癌诊断测试市场提供了巨大的成长机会。微创诊断工具的开发提高了患者的依从性并扩大了市场渗透率。由于医疗基础设施投资增加以及政府对癌症筛检的支持举措，新兴国家的潜力尚未开发。诊断解决方案提供者和医疗保健组织之间的合作可以加速创新并扩大服务提供。此外，对个人化医疗和精准诊断的日益关注为市场扩张提供了新的途径。

本报告提供全球子宫癌症诊断检验市场相关调查，提供癌症各类型，诊断检验各类型，各终端用户，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 摘要整理

第2章 市场简介

第3章 子宫癌症诊断检验市场观点

第4章 全球子宫癌症诊断检验市场- 主要调查内容

第5章 北美的子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第6章 南美的子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第7章 欧洲的子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第8章 中国以外亚太地区的子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第9章 中国的子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第10章 中东·非洲的子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第11章 预测要素:相关性及影响

第12章 竞争情形

  • 竞争仪表板
  • 企业简介(详细内容- 概要，财务，策略，最近的趋势)
  • 主要人物
    • Abbott
    • Roche Holdings AG
    • Siemens AG
    • Danaher
    • BioMerieux SA

第13章 全球子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)，各地区

第14章 全球子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)，癌症各类型

第15章 全球子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)，诊断检验各类型

第16章 全球子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)，各终端用户

第17章 全球子宫癌症诊断检验市场分析(2019年～2024年)及预测(2025年～2032年)

第18章 所使用的假设和缩写

第19章 调查手法

简介目录
Product Code: PMRREP17005

Persistence Market Research has recently released a comprehensive report on the global Uterine Cancer Diagnostic Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Uterine Cancer Diagnostic Testing Market Size (2025E): US$ 3,547.10 Mn
  • Projected Market Value (2032F): US$ 6,738.90 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.60%

Uterine Cancer Diagnostic Testing Market - Report Scope:

The global uterine cancer diagnostic testing market comprises diagnostic solutions such as ultrasound scanning, biopsy procedures, and blood tests aimed at detecting uterine cancer, which includes endometrial carcinoma and uterine sarcoma. The market growth is driven by the increasing prevalence of uterine cancer, advancements in diagnostic technologies, and the rising geriatric population. Improved healthcare infrastructure, awareness programs, and government initiatives also support market expansion.

Market Drivers:

Several factors are propelling the growth of the global uterine cancer diagnostic testing market. The rising prevalence of uterine cancer, particularly among post-menopausal and obese women, underscores the demand for early detection methods. Advances in diagnostic techniques, such as transvaginal ultrasound scanning and CA125 tumor marker blood tests, have improved accuracy and reliability, fueling market adoption. Increasing healthcare expenditure, especially in emerging economies, supports the development and accessibility of diagnostic solutions. Furthermore, government initiatives promoting women's health and cancer screenings, combined with rising awareness about early diagnosis, contribute significantly to market growth.

Market Restraints:

Despite the promising growth trajectory, the uterine cancer diagnostic testing market faces several challenges. High costs associated with advanced diagnostic procedures and limited healthcare infrastructure in certain regions can hinder market penetration. Awareness about uterine cancer diagnosis remains low in developing countries, impacting timely detection and treatment. The complexity and invasiveness of certain diagnostic procedures, such as dilation and curettage, may deter patients, particularly in regions with cultural and social barriers to medical intervention.

Market Opportunities:

The uterine cancer diagnostic testing market offers significant growth opportunities driven by technological advancements and expanding healthcare access. Development of minimally invasive diagnostic tools enhances patient compliance and broadens market adoption. Emerging economies present untapped potential due to increasing investments in healthcare infrastructure and government-backed initiatives for cancer screenings. Partnerships between diagnostic solution providers and healthcare organizations can accelerate innovation and expand service delivery. Additionally, the growing focus on personalized medicine and precision diagnostics provides new avenues for market expansion.

Key Questions Answered in the Report:

1. What are the primary factors driving the global growth of the uterine cancer diagnostic testing market?

2. Which diagnostic solutions are gaining the highest adoption across different regions?

3. How are advancements in diagnostic technologies shaping the competitive landscape of the uterine cancer diagnostic testing market?

4. Who are the key players in the uterine cancer diagnostic testing market, and what strategies are they employing to maintain their market positions?

5. What are the emerging trends and future outlooks for the global uterine cancer diagnostic testing market?

Competitive Intelligence and Business Strategy:

Leading companies in the global uterine cancer diagnostic testing market, such as Siemens Healthineers, Hologic, and GE Healthcare, are focusing on technological innovations and expanding their product portfolios to gain a competitive edge. These companies are leveraging collaborations with healthcare providers and research institutions to accelerate the development of advanced diagnostic solutions. Investments in AI-based imaging and non-invasive diagnostic technologies further support market growth. Additionally, companies are emphasizing affordability and accessibility to cater to diverse patient demographics, particularly in emerging economies.

Key Companies Profiled:

  • Abbott
  • Roche Holdings AG
  • Siemens AG
  • Danaher
  • BioMerieux SA
  • Others

Uterine Cancer Diagnostic Testing Market Segmentation:

By Cancer Type:

  • Endometrial Carcinoma
  • Uterine Sarcoma

By Diagnostic Test Type:

  • Ultrasound Scanning
  • Biopsy Procedures
  • Blood Tests

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Specialized Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Europe
  • Latin America
  • South East Asia & Pacific
  • Middle East & Africa (MEA)
  • China
  • Japan

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Uterine Cancer Diagnostic Testing Market View Point

  • 3.1. Macro-Economic Factors
  • 3.2. Market Drivers and Restraints
  • 3.3. Opportunity Analysis
  • 3.4. Global Key trends
  • 3.5. Reimbursement Scenario

4. Global Uterine Cancer Diagnostic Testing Market - Key Inclusions

  • 4.1. Regional Average Pricing Analysis
  • 4.2. Parent Market Assessment
  • 4.3. Epidemiology

5. North America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 5.1. Introduction
  • 5.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 5.2.1. U.S.
    • 5.2.2. Canada
  • 5.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 5.3.1. U.S.
    • 5.3.2. Canada
  • 5.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 5.4.1. Uterine Sarcoma
    • 5.4.2. Endometrial Carcinomas
  • 5.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 5.5.1. Uterine Sarcoma
    • 5.5.2. Endometrial Carcinomas
  • 5.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 5.6.1. Ultrasound Scanning
      • 5.6.1.1. Abdominal Ultrasound
      • 5.6.1.2. Transvaginal Ultrasound
    • 5.6.2. Biopsy
      • 5.6.2.1. Endometrial Biopsy
      • 5.6.2.2. Hysteroscopy
      • 5.6.2.3. Dilation and curettage
    • 5.6.3. Blood tests
      • 5.6.3.1. Complete blood Count
      • 5.6.3.2. CA-125 blood test
  • 5.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 5.7.1. Ultrasound Scanning
      • 5.7.1.1. Abdominal Ultrasound
      • 5.7.1.2. Transvaginal Ultrasound
    • 5.7.2. Biopsy
      • 5.7.2.1. Endometrial Biopsy
      • 5.7.2.2. Hysteroscopy
      • 5.7.2.3. Dilation and curettage
    • 5.7.3. Blood tests
      • 5.7.3.1. Complete blood Count
      • 5.7.3.2. CA-125 blood test
  • 5.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 5.8.1. Hospitals
    • 5.8.2. Ambulatory Surgical Centers
    • 5.8.3. Cancer Research Centers
    • 5.8.4. Specialized Clinics
    • 5.8.5. Diagnostic Laboratories
    • 5.8.6. Others
  • 5.9. Market Size Analysis 2025 - 2032, By End User
    • 5.9.1. Hospitals
    • 5.9.2. Ambulatory Surgical Centers
    • 5.9.3. Cancer Research Centers
    • 5.9.4. Specialized Clinics
    • 5.9.5. Diagnostic Laboratories
    • 5.9.6. Others
  • 5.10. Drivers and Restraints: Impact Analysis
  • 5.11. Market Attractiveness Analysis
    • 5.11.1. By Cancer Type
    • 5.11.2. By Test Type
    • 5.11.3. By End user
    • 5.11.4. By Country

6. Latin America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 6.1. Introduction
  • 6.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 6.2.1. Brazil
    • 6.2.2. Mexico
    • 6.2.3. Rest of Latin America
  • 6.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Rest of Latin America
  • 6.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 6.4.1. Uterine Sarcoma
    • 6.4.2. Endometrial Carcinomas
  • 6.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 6.5.1. Uterine Sarcoma
    • 6.5.2. Endometrial Carcinomas
  • 6.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 6.6.1. Ultrasound Scanning
      • 6.6.1.1. Abdominal Ultrasound
      • 6.6.1.2. Transvaginal Ultrasound
    • 6.6.2. Biopsy
      • 6.6.2.1. Endometrial Biopsy
      • 6.6.2.2. Hysteroscopy
      • 6.6.2.3. Dilation and curettage
    • 6.6.3. Blood tests
      • 6.6.3.1. Complete blood Count
      • 6.6.3.2. CA-125 blood test
  • 6.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 6.7.1. Ultrasound Scanning
      • 6.7.1.1. Abdominal Ultrasound
      • 6.7.1.2. Transvaginal Ultrasound
    • 6.7.2. Biopsy
      • 6.7.2.1. Endometrial Biopsy
      • 6.7.2.2. Hysteroscopy
      • 6.7.2.3. Dilation and curettage
    • 6.7.3. Blood tests
      • 6.7.3.1. Complete blood Count
      • 6.7.3.2. CA-125 blood test
  • 6.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 6.8.1. Hospitals
    • 6.8.2. Ambulatory Surgical Centers
    • 6.8.3. Cancer Research Centers
    • 6.8.4. Specialized Clinics
    • 6.8.5. Diagnostic Laboratories
    • 6.8.6. Others
  • 6.9. Market Size Analysis 2025 - 2032, By End User
    • 6.9.1. Hospitals
    • 6.9.2. Ambulatory Surgical Centers
    • 6.9.3. Cancer Research Centers
    • 6.9.4. Specialized Clinics
    • 6.9.5. Diagnostic Laboratories
    • 6.9.6. Others
  • 6.10. Drivers and Restraints: Impact Analysis
  • 6.11. Market Attractiveness Analysis
    • 6.11.1. By Cancer Type
    • 6.11.2. By Test Type
    • 6.11.3. By End user
    • 6.11.4. By Country

7. Europe Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 7.2.1. Germany
    • 7.2.2. U.K.
    • 7.2.3. France
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Poland
    • 7.2.7. Russia
    • 7.2.8. Rest of Europe
  • 7.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Poland
    • 7.3.7. Russia
    • 7.3.8. Rest of Europe
  • 7.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 7.4.1. Uterine Sarcoma
    • 7.4.2. Endometrial Carcinomas
  • 7.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 7.5.1. Uterine Sarcoma
    • 7.5.2. Endometrial Carcinomas
  • 7.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 7.6.1. Ultrasound Scanning
      • 7.6.1.1. Abdominal Ultrasound
      • 7.6.1.2. Transvaginal Ultrasound
    • 7.6.2. Biopsy
      • 7.6.2.1. Endometrial Biopsy
      • 7.6.2.2. Hysteroscopy
      • 7.6.2.3. Dilation and curettage
    • 7.6.3. Blood tests
      • 7.6.3.1. Complete blood Count
      • 7.6.3.2. CA-125 blood test
  • 7.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 7.7.1. Ultrasound Scanning
      • 7.7.1.1. Abdominal Ultrasound
      • 7.7.1.2. Transvaginal Ultrasound
    • 7.7.2. Biopsy
      • 7.7.2.1. Endometrial Biopsy
      • 7.7.2.2. Hysteroscopy
      • 7.7.2.3. Dilation and curettage
    • 7.7.3. Blood tests
      • 7.7.3.1. Complete blood Count
      • 7.7.3.2. CA-125 blood test
  • 7.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 7.8.1. Hospitals
    • 7.8.2. Ambulatory Surgical Centers
    • 7.8.3. Cancer Research Centers
    • 7.8.4. Specialized Clinics
    • 7.8.5. Diagnostic Laboratories
    • 7.8.6. Others
  • 7.9. Market Size Analysis 2025 - 2032, By End User
    • 7.9.1. Hospitals
    • 7.9.2. Ambulatory Surgical Centers
    • 7.9.3. Cancer Research Centers
    • 7.9.4. Specialized Clinics
    • 7.9.5. Diagnostic Laboratories
    • 7.9.6. Others
  • 7.10. Drivers and Restraints: Impact Analysis
  • 7.11. Market Attractiveness Analysis
    • 7.11.1. By Cancer Type
    • 7.11.2. By Test Type
    • 7.11.3. By End user
    • 7.11.4. By Country

8. Asia Pacific Excluding China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 8.1. Introduction
  • 8.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. Australia and New Zealand
    • 8.2.5. Rest of APAC
  • 8.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. India
    • 8.3.3. Japan
    • 8.3.4. Australia and New Zealand
    • 8.3.5. Rest of APAC
  • 8.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 8.4.1. Uterine Sarcoma
    • 8.4.2. Endometrial Carcinomas
  • 8.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 8.5.1. Uterine Sarcoma
    • 8.5.2. Endometrial Carcinomas
  • 8.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 8.6.1. Ultrasound Scanning
      • 8.6.1.1. Abdominal Ultrasound
      • 8.6.1.2. Transvaginal Ultrasound
    • 8.6.2. Biopsy
      • 8.6.2.1. Endometrial Biopsy
      • 8.6.2.2. Hysteroscopy
      • 8.6.2.3. Dilation and curettage
    • 8.6.3. Blood tests
      • 8.6.3.1. Complete blood Count
      • 8.6.3.2. CA-125 blood test
  • 8.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 8.7.1. Ultrasound Scanning
      • 8.7.1.1. Abdominal Ultrasound
      • 8.7.1.2. Transvaginal Ultrasound
    • 8.7.2. Biopsy
      • 8.7.2.1. Endometrial Biopsy
      • 8.7.2.2. Hysteroscopy
      • 8.7.2.3. Dilation and curettage
    • 8.7.3. Blood tests
      • 8.7.3.1. Complete blood Count
      • 8.7.3.2. CA-125 blood test
  • 8.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 8.8.1. Hospitals
    • 8.8.2. Ambulatory Surgical Centers
    • 8.8.3. Cancer Research Centers
    • 8.8.4. Specialized Clinics
    • 8.8.5. Diagnostic Laboratories
    • 8.8.6. Others
  • 8.9. Market Size Analysis 2025 - 2032, By End User
    • 8.9.1. Hospitals
    • 8.9.2. Ambulatory Surgical Centers
    • 8.9.3. Cancer Research Centers
    • 8.9.4. Specialized Clinics
    • 8.9.5. Diagnostic Laboratories
    • 8.9.6. Others
  • 8.10. Drivers and Restraints: Impact Analysis
  • 8.11. Market Attractiveness Analysis
    • 8.11.1. By Cancer Type
    • 8.11.2. By Test Type
    • 8.11.3. By End user
    • 8.11.4. By Country

9. China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 9.2.1. Uterine Sarcoma
    • 9.2.2. Endometrial Carcinomas
  • 9.3. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 9.3.1. Uterine Sarcoma
    • 9.3.2. Endometrial Carcinomas
  • 9.4. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 9.4.1. Ultrasound Scanning
      • 9.4.1.1. Abdominal Ultrasound
      • 9.4.1.2. Transvaginal Ultrasound
    • 9.4.2. Biopsy
      • 9.4.2.1. Endometrial Biopsy
      • 9.4.2.2. Hysteroscopy
      • 9.4.2.3. Dilation and curettage
    • 9.4.3. Blood tests
      • 9.4.3.1. Complete blood Count
      • 9.4.3.2. CA-125 blood test
  • 9.5. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 9.5.1. Ultrasound Scanning
      • 9.5.1.1. Abdominal Ultrasound
      • 9.5.1.2. Transvaginal Ultrasound
    • 9.5.2. Biopsy
      • 9.5.2.1. Endometrial Biopsy
      • 9.5.2.2. Hysteroscopy
      • 9.5.2.3. Dilation and curettage
    • 9.5.3. Blood tests
      • 9.5.3.1. Complete blood Count
      • 9.5.3.2. CA-125 blood test
  • 9.6. Historical Market Size Analysis 2019 - 2024, By End User
    • 9.6.1. Hospitals
    • 9.6.2. Ambulatory Surgical Centers
    • 9.6.3. Cancer Research Centers
    • 9.6.4. Specialized Clinics
    • 9.6.5. Diagnostic Laboratories
    • 9.6.6. Others
  • 9.7. Market Size Analysis 2025 - 2032, By End User
    • 9.7.1. Hospitals
    • 9.7.2. Ambulatory Surgical Centers
    • 9.7.3. Cancer Research Centers
    • 9.7.4. Specialized Clinics
    • 9.7.5. Diagnostic Laboratories
    • 9.7.6. Others
  • 9.8. Drivers and Restraints: Impact Analysis
  • 9.9. Market Attractiveness Analysis
    • 9.9.1. By Cancer Type
    • 9.9.2. By Test Type
    • 9.9.3. By End user
    • 9.9.4. By Country

10. Middle East and Africa (MEA) Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 10.2.1. South Africa
    • 10.2.2. Saudi Arabia
    • 10.2.3. Rest of MEA
  • 10.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 10.3.1. South Africa
    • 10.3.2. Saudi Arabia
    • 10.3.3. Rest of MEA
  • 10.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 10.4.1. Uterine Sarcoma
    • 10.4.2. Endometrial Carcinomas
  • 10.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 10.5.1. Uterine Sarcoma
    • 10.5.2. Endometrial Carcinomas
  • 10.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 10.6.1. Ultrasound Scanning
      • 10.6.1.1. Abdominal Ultrasound
      • 10.6.1.2. Transvaginal Ultrasound
    • 10.6.2. Biopsy
      • 10.6.2.1. Endometrial Biopsy
      • 10.6.2.2. Hysteroscopy
      • 10.6.2.3. Dilation and curettage
    • 10.6.3. Blood tests
      • 10.6.3.1. Complete blood Count
      • 10.6.3.2. CA-125 blood test
  • 10.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 10.7.1. Ultrasound Scanning
      • 10.7.1.1. Abdominal Ultrasound
      • 10.7.1.2. Transvaginal Ultrasound
    • 10.7.2. Biopsy
      • 10.7.2.1. Endometrial Biopsy
      • 10.7.2.2. Hysteroscopy
      • 10.7.2.3. Dilation and curettage
    • 10.7.3. Blood tests
      • 10.7.3.1. Complete blood Count
      • 10.7.3.2. CA-125 blood test
  • 10.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 10.8.1. Hospitals
    • 10.8.2. Ambulatory Surgical Centers
    • 10.8.3. Cancer Research Centers
    • 10.8.4. Specialized Clinics
    • 10.8.5. Diagnostic Laboratories
    • 10.8.6. Others
  • 10.9. Market Size Analysis 2025 - 2032, By End User
    • 10.9.1. Hospitals
    • 10.9.2. Ambulatory Surgical Centers
    • 10.9.3. Cancer Research Centers
    • 10.9.4. Specialized Clinics
    • 10.9.5. Diagnostic Laboratories
    • 10.9.6. Others
  • 10.10. Drivers and Restraints: Impact Analysis
  • 10.11. Market Attractiveness Analysis
    • 10.11.1. By Cancer Type
    • 10.11.2. By Test Type
    • 10.11.3. By End user
    • 10.11.4. By Country

11. Forecast Factors: Relevance and Impact

12. Competition Landscape

  • 12.1. Competition Dashboard
  • 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3. Key Players
    • 12.3.1. Abbott
    • 12.3.2. Roche Holdings AG
    • 12.3.3. Siemens AG
    • 12.3.4. Danaher
    • 12.3.5. BioMerieux SA

13. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

  • 13.1. Introduction
    • 13.1.1. Basis Point Share (BPS) Analysis by Region
    • 13.1.2. Y-o-Y Growth Projections by Region
  • 13.2. Historical Market Size Analysis 2019 - 2024, By Region
    • 13.2.1. North America
    • 13.2.2. Latin America
    • 13.2.3. Europe
    • 13.2.4. Asia Pacific Excluding China
    • 13.2.5. China
    • 13.2.6. Middle East and Africa (MEA)
  • 13.3. Market Size Analysis 2025 - 2032, By Region
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. Asia Pacific Excluding China
    • 13.3.5. China
    • 13.3.6. Middle East and Africa (MEA)
  • 13.4. Market Attractiveness Analysis by Region

14. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Cancer Type

  • 14.1. Introduction
    • 14.1.1. Basis Point Share (BPS) Analysis by Product Type
    • 14.1.2. Y-o-Y Growth Projections by Product Type
  • 14.2. Historical Market Size Analysis 2019 - 2024, By Cancer Type
    • 14.2.1. Uterine Sarcoma
    • 14.2.2. Endometrial Carcinomas
  • 14.3. Market Size Analysis 2025 - 2032, By Cancer Type
    • 14.3.1. Uterine Sarcoma
    • 14.3.2. Endometrial Carcinomas
  • 14.4. Market Attractiveness Analysis by Cancer Type

15. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Diagnostic Test Type

  • 15.1. Introduction
    • 15.1.1. Basis Point Share (BPS) Analysis by Test Type
    • 15.1.2. Y-o-Y Growth Projections by Test Type
  • 15.2. Historical Market Size Analysis 2019 - 2024, By Test Type
    • 15.2.1. Ultrasound Scanning
      • 15.2.1.1. Abdominal Ultrasound
      • 15.2.1.2. Transvaginal Ultrasound
    • 15.2.2. Biopsy
      • 15.2.2.1. Endometrial Biopsy
      • 15.2.2.2. Hysteroscopy
      • 15.2.2.3. Dilation and curettage
    • 15.2.3. Blood tests
      • 15.2.3.1. Complete blood Count
      • 15.2.3.2. CA-125 blood test
  • 15.3. Market Size Analysis 2025 - 2032, By Test Type
    • 15.3.1. Ultrasound Scanning
      • 15.3.1.1. Abdominal Ultrasound
      • 15.3.1.2. Transvaginal Ultrasound
    • 15.3.2. Biopsy
      • 15.3.2.1. Endometrial Biopsy
      • 15.3.2.2. Hysteroscopy
      • 15.3.2.3. Dilation and curettage
    • 15.3.3. Blood tests
      • 15.3.3.1. Complete blood Count
      • 15.3.3.2. CA-125 blood test
  • 15.4. Market Attractiveness Analysis by Test Type

16. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By End User

  • 16.1. Introduction
    • 16.1.1. Basis Point Share (BPS) Analysis by End User
    • 16.1.2. Y-o-Y Growth Projections by End User
  • 16.2. Historical Market Size Analysis 2019 - 2024, By End User
    • 16.2.1. Hospitals
    • 16.2.2. Ambulatory Surgical Centers
    • 16.2.3. Cancer Research Centers
    • 16.2.4. Specialized Clinics
    • 16.2.5. Diagnostic Laboratories
    • 16.2.6. Others
  • 16.3. Market Size Analysis 2025 - 2032, By End User
    • 16.3.1. Hospitals
    • 16.3.2. Ambulatory Surgical Centers
    • 16.3.3. Cancer Research Centers
    • 16.3.4. Specialized Clinics
    • 16.3.5. Diagnostic Laboratories
    • 16.3.6. Others
  • 16.4. Market Attractiveness Analysis by End User

17. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 17.1. Market Size and Y-o-Y Growth
  • 17.2. Absolute $ Opportunity

18. Assumptions and Acronyms Used

A glossary of assumption and acronyms used in the report

19. Research Methodology